ANDA Labeling: Helpful Hints and Resources

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

OTC Monograph Reform: OTC Sunscreen Drugs

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Direct: Combating Rare Diseases at the FDA

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

Drug Master File (DMF) Submissions on New FDA Form 3938

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA Expert Panel on Food Allergies

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

Product Specific Guidances Webinar – Opening Remarks

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

2025 FDA Achievements

FDA’s Rare Disease Day 2026 – An Event for Patients

January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting

FDA Celebrates 120 Years